

Special Issue

Neoadjuvant Chemotherapy in Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer remains one of the most aggressive malignancies, with limited treatment options and poor overall survival rates. Neoadjuvant chemotherapy (NAC) has gained increasing attention as a strategy to improve surgical outcomes, enhance tumor resectability, and potentially increase long-term survival in patients with (borderline) resectable and locally advanced pancreatic cancer. However, careful patient selection is crucial to ensure that only those who will genuinely benefit from surgery proceed to resection, as not all patients respond favorably to NAC. Identifying reliable biomarkers and imaging criteria to predict response and optimize treatment decisions remains a key challenge. This Special Issue examines the evolving role of NAC in pancreatic cancer, focusing on treatment protocols, clinical outcomes, resistance mechanisms, patient selection, and emerging biomarkers. We invite original research, reviews, and clinical studies offering insights into optimizing NAC strategies and improving patient prognosis. The goal is to advance understanding and discuss integrating NAC into standard treatment and selecting surgical candidates post-NAC.

Guest Editor

Prof. Dr. Casper H. J. Van Eijck
Department of Surgery, Erasmus MC, University Medical Center
Rotterdam, 3000 CA Rotterdam, The Netherlands

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/232899

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)